BIOMAT Database Logo BIOMAT Database Logo

Mavacamten for Obstructive Hypertrophic Cardiomyopathy in China. 2023

Milind Y Desai
Hypertrophic Cardiomyopathy Center, Heart Vascular Thoracic Institute, Cleveland Clinic, Cleveland, Ohio.

UI MeSH Term Description Entries

Related Publications

Milind Y Desai
Mavacamten for hypertrophic obstructive cardiomyopathy.
January 2021, Lancet (London, England),
Milind Y Desai
Mavacamten (Camzyos) for obstructive hypertrophic cardiomyopathy.
June 2022, The Medical letter on drugs and therapeutics,
Milind Y Desai
Mavacamten for hypertrophic obstructive cardiomyopathy - Authors' reply.
January 2021, Lancet (London, England),
Milind Y Desai
New Era: Mavacamten for Obstructive Hypertrophic Cardiomyopathy.
January 2023, Cardiovascular & hematological agents in medicinal chemistry,
Milind Y Desai
Genotype Influences Mavacamten Responsiveness in Obstructive Hypertrophic Cardiomyopathy.
February 2024, Mayo Clinic proceedings,
Milind Y Desai
Mavacamten improves symptoms in obstructive hypertrophic cardiomyopathy patients.
May 2023, Trends in pharmacological sciences,
Milind Y Desai
Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy: A Clinical Trial.
June 2019, Annals of internal medicine,
Milind Y Desai
Mavacamten, a Novel Therapeutic Strategy for Obstructive Hypertrophic Cardiomyopathy.
June 2021, Current cardiology reports,
Milind Y Desai
Alcohol Septal Ablation or Mavacamten for Obstructive Hypertrophic Cardiomyopathy.
October 2023, Journal of clinical medicine,
Milind Y Desai
Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy.
November 2023, European heart journal,
Copied contents to your clipboard!